Announced details
Metastatic colorectal cancer with RAS mutations
Sum of tumor diameters decreased by approximately 50% at most; 5 of the 10 treated patients were potential candidates for tumor resection with curative intent; 0 cases of dose-limiting toxicity
10 patients treated in the Phase Ib trial; 3 patients enrolled at the maximum dose of 500 mg/m² (3 additional patients planned)
Rights licensor/development partner for SP-05
The text indicates that it is a Swedish pharmaceutical development company, but its location, representative, capital, year of establishment and other details are Not disclosed
Trial sites in Germany, Spain, Austria and Greece (specific locations are Not disclosed)
A medium- to long-term impact is expected, but there will be no impact on FY2026 earnings
The company does not address Contract Value / Offering price.
Disclosure by Isofol Medical AB dated 10 November 2026 (local time); World Health Organization (WHO)
| Item | Details |
|---|---|
| Names of Products / Services Covered | SP-05 (generic name: arfolitixorin sulfate) |
| Counterparty | Isofol Medical AB |
| Counterparty overview | The text indicates that it is a Swedish pharmaceutical development company, but its location, representative, capital, year of establishment and other details are Not disclosed |
| Relationship with the Company | Rights licensor/development partner for SP-05 |
| Applicable area | Metastatic colorectal cancer with RAS mutations |
| Location | Trial sites in Germany, Spain, Austria and Greece (specific locations are Not disclosed) |
| Location scale | 15–20 sites (planned Phase II portion) |
| Quantitative Effects | Sum of tumor diameters decreased by approximately 50% at most; 5 of the 10 treated patients were potential candidates for tumor resection with curative intent; 0 cases of dose-limiting toxicity |
| Usage history | 10 patients treated in the Phase Ib trial; 3 patients enrolled at the maximum dose of 500 mg/m² (3 additional patients planned) |
| Impact on Business Performance | A medium- to long-term impact is expected, but there will be no impact on FY2026 earnings |
| Source | Disclosure by Isofol Medical AB dated 10 November 2026 (local time); World Health Organization (WHO) |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Phase Ib trial is evaluating the safety and tolerability of a new arfolitixorin regimen in combination with standard treatment. For Phase II, the company said it will expand the trial sites and participating countries to strengthen its geographic base and patient recruitment capabilities, leading to faster and more efficient trial execution.